BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is -4.09% lower on its value in year-to-date trading and has touched a low of $7.61 and a high of $19.99 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BCRX stock was last observed hovering at around $10.63 in the last trading session, with the day’s gains setting it 0.38% off its average median price target of $15.50 for the next 12 months. It is also 63.3% off the consensus price target high of $30.00 offered by 12 analysts, but current levels are -10.1% lower than the price target low of $10.00 for the same period.
Currently trading at $11.01, the stock is 1.55% and -4.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.99 million and changing 3.57% at the moment leaves the stock -6.26% off its SMA200. BCRX registered -20.10% loss for a year compared to 6-month loss of 1.01%.
The stock witnessed a 1.66% gain in the last 1 month and extending the period to 3 months gives it a -22.14%, and is 10.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.35% over the week and 5.33% over the month.
BioCryst Pharmaceuticals Inc. (BCRX) has around 358 employees, a market worth around $1.98B and $238.40M in sales. Profit margin for the company is -81.10%. Distance from 52-week low is 44.68% and -44.92% from its 52-week high. The company has generated returns on investments over the last 12 months (-25.90%).
BioCryst Pharmaceuticals Inc. (BCRX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for BioCryst Pharmaceuticals Inc. (BCRX) is a “Overweight”. 12 analysts offering their recommendations for the stock have an average rating of 2.50, where 6 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
BioCryst Pharmaceuticals Inc. is expected to release its quarterly report on 05/04/2023.The EPS is expected to grow by 6.00% this year.
BioCryst Pharmaceuticals Inc. (BCRX) Top Institutional Holders
The shares outstanding are 186.18M, and float is at 184.56M with Short Float at 14.76%.
BioCryst Pharmaceuticals Inc. (BCRX) Insider Activity
A total of 29 insider transactions have happened at BioCryst Pharmaceuticals Inc. (BCRX) in the last six months, with sales accounting for 10 and purchases happening 19 times. The most recent transaction is an insider sale by Stonehouse Jon P,the company’sPresident & CEO. SEC filings show that Stonehouse Jon P sold 14,100 shares of the company’s common stock on Dec 15 at a price of $10.90 per share for a total of $0.15 million. Following the sale, the insider now owns 0.89 million shares.
BioCryst Pharmaceuticals Inc. disclosed in a document filed with the SEC on Dec 15 that Thackray Helen M. (Chief R&D Officer) sold a total of 3,125 shares of the company’s common stock. The trade occurred on Dec 15 and was made at $10.89 per share for $34031.0. Following the transaction, the insider now directly holds 0.13 million shares of the BCRX stock.
Still, SEC filings show that on Dec 15, Doyle Anthony (Chief Financial Officer) disposed off 5,700 shares at an average price of $10.90 for $62130.0. The insider now directly holds 163,966 shares of BioCryst Pharmaceuticals Inc. (BCRX).
BioCryst Pharmaceuticals Inc. (BCRX): Who are the competitors?
The company’s main competitors (and peers) include CEL-SCI Corporation (CVM) that is trading -50.00% down over the past 12 months and Emergent BioSolutions Inc. (EBS) that is -72.09% lower over the same period. Sarepta Therapeutics Inc. (SRPT) is 102.25% up on the 1-year trading charts.